skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Glatiramer in the treatment of multiple sclerosis

(2372) Views  (479) Full article downloads

Authors: Syed A Rizvi, Edward Kim

Published Date February 2006 Volume 2006:1(3) Pages 283 - 289
DOI: http://dx.doi.org/10.2147/IJN.S

Syed A Rizvi, Edward Kim

Jennifer Moodie Department of Clinical Neurosciences, Brown Medical School, Rhode Island Hospital, Providence, RI, USA

Abstract: Multiple sclerosis (MS) is a disease of the central nervous system with both an inflammatory and degenerative component. The disease primarily affects young adults and results in significant physical and cognitive disability. Several disease-modifying agents are currently used in the management of multiple sclerosis. Glatiramer acetate (GA, Copaxone®, co-polymer 1) is a disease-modifying agent approved for the treatment of relapsing remitting multiple sclerosis. Apart from its unique mode of action, there is evidence pointing toward a possible neuroprotective role. This review will critically discuss GA’s potential mechanisms of action, the results of clinical trials, safety profile, and future directions of treatment.

Keywords: multiple sclerosis, disease-modifying agents, glatiramer acetate, clinical trials, MRI, neurodegeneration








Readers of this article also read:

Increased osteoblast adhesion on nanoparticulate crystalline hydroxyapatite functionalized with KRSR
Adverse effects of fullerenes on endothelial cells: Fullerenol C60(OH)24 induced tissue factor and ICAM-1 membrane expression and apoptosis in vitro
Evidence-based decision-making within the context of globalization: A “Why–What–How” for leaders and managers of health care organizations
Periosteoplasty for covering gingival recessions: Clinical results
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Amino acid management of Parkinson’s disease: a case study
Optimization of single-walled carbon nanotube solubility by noncovalent PEGylation using experimental design methods
Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines